Comparative Pharmacology
Head-to-head clinical analysis: STELARA versus STEQEYMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STELARA versus STEQEYMA.
STELARA vs STEQEYMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ustekinumab is a human IgG1κ monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit of human interleukin (IL)-12 and IL-23, thereby blocking IL-12 and IL-23 mediated cell signaling and cytokine cascades.
Steqeyma is a fully human monoclonal antibody that specifically binds to the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor. This blocks the IL-23-mediated signaling pathway, reducing the production of pro-inflammatory cytokines (e.g., IL-17, IL-22) involved in immune-mediated inflammatory diseases.
Plaque psoriasis/Psoriatic arthritis: 45 mg subcutaneously (SC) for patients ≤100 kg or 90 mg SC for patients >100 kg at Weeks 0 and 4, then every 12 weeks. Crohn’s disease/Ulcerative colitis: Weight-based single intravenous induction dose (~6 mg/kg) at Week 0, followed by 90 mg SC at Week 8 and every 8 weeks thereafter.
2 mg/kg intravenously every 8 hours
None Documented
None Documented
Terminal elimination half-life of approximately 3 weeks (range 15–32 days) in patients with psoriasis; supports subcutaneous dosing every 12 weeks.
Terminal elimination half-life is 18-22 hours in patients with normal renal function. Prolonged in renal impairment.
Primarily degraded into small peptides and individual amino acids; no significant renal or biliary excretion of intact antibody. Fecal excretion of degradation products is negligible.
Primarily eliminated via renal excretion (approximately 80% as unchanged drug) and biliary/fecal elimination (approximately 20%).
Category C
Category C
Interleukin Inhibitor
Interleukin Inhibitor